-
Product Insights
Nimbus Wind Farm
Nimbus Wind Farm is an Onshore Wind project located in Arkansas, United States. The project is owned and being developed by Scout Clean Energy LLC. The project is at the permitting stage. Empower your strategies with our Nimbus Wind Farm report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eganelisib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eganelisib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eganelisib in Non-Small Cell Lung Cancer Drug Details: Eganelisib is...
-
Product Insights
Axial Spondyloarthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Axial Spondyloarthritis - Drugs In Development, 2023’, provides an overview of the Axial Spondyloarthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Ankylosing Spondylitis (Bekhterev’s Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Ankylosing Spondylitis (Bekhterev's Disease) - Drugs In Development, 2023’, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMBS-2 in Colon Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMBS-2 in Colon Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMBS-2 in Colon Cancer Drug Details: NMBS-2 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMBS-2 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMBS-2 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMBS-2 in Pancreatic Cancer Drug Details: NMBS-2 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMBS-2 in Endometrial Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMBS-2 in Endometrial Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMBS-2 in Endometrial Cancer Drug Details: NMBS-2 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMBS-2 in Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMBS-2 in Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMBS-2 in Renal Cell Carcinoma Drug Details: NMBS-2 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMBS-2 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMBS-2 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMBS-2 in Non-Small Cell Lung Cancer Drug Details: NMBS-2 is...
-
Company Insights
GlaxoSmithKline Plc – Digital Transformation Strategies
GlaxoSmithKline digital transformation strategies report overview GlaxoSmithKline is harnessing the power of digital technologies such as AI, ML, and deep learning to accelerate the drug discovery and development process and reduce the time and operational costs. The annual ICT spending of GlaxoSmithKline was estimated at $892.7 million in 2023. A major share of this spending is earmarked for acquiring software, ICT services, and consulting from vendors. GlaxoSmithKline is a healthcare company that focuses on developing, manufacturing, and commercializing pharmaceuticals, vaccines,...